BioSpace News Archive

Lipocine Inc., a biopharmaceutical company, announced that data from the Phase 2 study of LPCN 1148 has been selected for a late breaking oral presentation at the European Association for the Study of Liver Congress, to take place June 5 to 8, 2024 in Milan, Italy.

Twist Bioscience Corporation today announced that it has granted a total of 87,200 restricted stock units (“RSUs”) to 26 recently hired individuals as an inducement material to their acceptance of employment with Twist.

Premier, Inc. is excited to announce a strategic partnership with AstraZeneca called Uncover CKD - Care Collective aiming to identify patients with undiagnosed clinical chronic kidney disease ; raise awareness of undiagnosed CKD among healthcare providers; and inform U.S. health systems that want to improve or develop and implement their strategies for CKD diagnosis, treatment and management.

4C Medical Technologies, Inc. has been granted Breakthrough Device designation by the U.S. Food and Drug Administration for the AltaValve™ System, a transcatheter mitral valve replacement device.

Axsome Therapeutics, Inc. announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will participate in two upcoming investor conferences.

Cartesian Therapeutics, Inc. reported financial results for the first quarter ended March 31, 2024, and recent corporate updates.

CRISPR Therapeutics announced new preclinical data presented at the 27th Annual Meeting of the American Society of Cell and Gene Therapy highlighting the Company’s approach to developing lipid nanoparticle based delivery for in vivo ocular gene editing.

PolyPid Ltd., a late-stage biopharma company aiming to improve surgical outcomes, provided a corporate update and reported financial results for the three months ended March 31, 2024.

Bio-Techne Corporation announced that Kim Kelderman, President and Chief Executive Officer, will present at the BofA Securities Health Care Conference on Tuesday, May 14, 2024, at 2:20 p.m. PDT.

Acepodia announced preliminary data from its Phase 1 dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin’s lymphoma.